These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62 related articles for article (PubMed ID: 3137416)
41. The Salmonella mutagenicity assay: promises and problems. Prival MJ Ann N Y Acad Sci; 1983; 407():154-63. PubMed ID: 6349472 [No Abstract] [Full Text] [Related]
42. Genotoxicity of nicotine and cotinine in the bacterial luminescence test. Yim SH; Hee SS Mutat Res; 1995 Dec; 335(3):275-83. PubMed ID: 8524343 [TBL] [Abstract][Full Text] [Related]
43. Activation of xenobiotics by human polymorphonuclear leukocytes via reactive oxygen-dependent reactions. Trush MA; Kensler TW; Seed JL Adv Exp Med Biol; 1986; 197():311-21. PubMed ID: 2429521 [No Abstract] [Full Text] [Related]
45. Detection of metabolic carcinogen intermediates in urine of carcinogen-fed rats by means of bacterial mutagenesis. Commoner B; Vithayathil AJ; Henry JI Nature; 1974 Jun; 249(460):850-2. PubMed ID: 4209968 [No Abstract] [Full Text] [Related]
46. Comutagenicity, competitive enzyme substrates, and in vitro carcinogenicity assays. Ashby J; Styles JA Mutat Res; 1978 Aug; 54(1):105-12. PubMed ID: 97523 [No Abstract] [Full Text] [Related]
47. Comparisons between in vivo and in vitro systems: the in vivo equivalent dose concept. Paolini M; Cantelli Forti G; Bauer C Mutagenesis; 1988 Nov; 3(6):527-31. PubMed ID: 3070294 [No Abstract] [Full Text] [Related]
48. A pre-validation transferability study of the GreenScreen HC GADD45a-GFP assay with a metabolic activation system (S9). Billinton N; Bruce S; Hansen JR; Hastwell PW; Jagger C; McComb C; Klug ML; Pant K; Rabinowitz A; Rees R; Tate M; Vinggaard AM; Walmsley RM Mutat Res; 2010 Jul; 700(1-2):44-50. PubMed ID: 20452458 [TBL] [Abstract][Full Text] [Related]
49. Carcinogenic azo dyes. XI. Analysis of biliary and urinary metabolities of 3'-methyl-4-(methylamino)azobenzene in rat. Mori Y; Yamamoto T; Toyoshi K Chem Pharm Bull (Tokyo); 1979 Feb; 27(2):379-85. PubMed ID: 109219 [No Abstract] [Full Text] [Related]
50. The possible role of azoreduction in the bacterial mutagenicity of 4-dimethylaminoazobenzene (DAB) and 2 of its analogues (6BT and 5I). Ashby J; Lefevre PA; Callander RD Mutat Res; 1983 Mar; 116(3-4):271-9. PubMed ID: 6403852 [TBL] [Abstract][Full Text] [Related]
51. The effects of pre-incubation period and norharman on the mutagenic potency of 4-dimethylaminoazobenzene and 3'-methyl-4-dimethylaminoazobenzene in S. typhimurium. Lefevre PA; Ashby J Carcinogenesis; 1981; 2(9):927-31. PubMed ID: 6794927 [TBL] [Abstract][Full Text] [Related]
52. Use of an in vivo/in vitro rat liver DNA repair assay to predict the relative rodent hepatocarcinogenic potency of 3 new azo mutagens. Beije B; Ashby J Carcinogenesis; 1985 Apr; 6(4):611-5. PubMed ID: 3921275 [TBL] [Abstract][Full Text] [Related]
53. An assessment of the in vivo rat hepatocyte DNA-repair assay. Ashby J; Lefevre PA; Burlinson B; Penman MG Mutat Res; 1985; 156(1-2):1-18. PubMed ID: 3923346 [TBL] [Abstract][Full Text] [Related]
54. Observed convergence of the Salmonella plate and pre-incubation assays when employing varying levels of S9. Callander RD Mutagenesis; 1986 Nov; 1(6):439-43. PubMed ID: 3137416 [TBL] [Abstract][Full Text] [Related]